An Ebola vaccine has proven to be 100 percent effective during test trials in Guinea. Of the 5,837 people who received the vaccine, none came down with Ebola after 10 days.
Should it be endorsed, the vaccine could provide a vital defence against Ebola outbreaks in the future. The epidemic in 2014, which affected nearly 30,000 people and took more than 11,000 lives, has provided governments, businesses and scientific institutions the necessary push to complete an effective vaccine.
By way of comparison, there were 23 cases in the group that didn’t receive the vaccine. “We were able to estimate the efficacy of the vaccine as being 100 percent in a trial,” Ira Longini, a biostatistician who worked on the project said.
All of the trial subjects were then randomised and received the vaccine immediately, or up to three weeks later. The first results were so promising, however, that the trial’s design was changed so everyone could access the vaccine immediately, including children.
As The New York Times reports, it only combats one of the two most common Ebola strains. The shot also comes with some reported side effects, such as joint pain and headaches. Questions have also been raised over the long-term effectiveness of the vaccine.
” While these compelling results come too late for those who lost their lives during West Africa’s Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless,” Dr Marie-Paule Kieny, Assistant Director-General for Health Systems and Innovation at WHO, and the study’s lead author said.